CD27 and acute myeloid leukemia: The pilot trial of a fourth-generation apoptosis inducible CAR targeting CD123 (CD123-scFv/CD28/CD137/CD27/CD3ζ-iCasp9) decreased disease burden from 60 to 45% in a 47-year-old patient with AML post-allo-SCT relapse [152].